Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI response largely reflects the labeled content on nephrotoxicity risk and management, with multiple statements supported by WARNINGS/PRECAUTIONS and DOSAGE sections. Several claims are not supported by the provided label sections, including explicit IV vs oral risk comparisons and some renal- perfusion related factors.
Category Scores
Accurate Statements
Acyclovir can cause crystal nephropathy and other kidney issues, especially when risk factors are present.
5. WARNINGS AND PRECAUTIONS; 2. DOSAGE AND ADMINISTRATION
Rapid IV infusion (shorter than about 60 minutes) raises the chance of crystal formation in the renal tubules.
2. DOSAGE AND ADMINISTRATION; 5. WARNINGS AND PRECAUTIONS
Preexisting renal impairment (reduced creatinine clearance or eGFR).
2. DOSAGE AND ADMINISTRATION; 5. WARNINGS AND PRECAUTIONS; 8. Geriatric Use
Elderly age, which often comes with reduced renal function.
8. Geriatric Use
Volume depletion or dehydration (vomiting, diarrhea, poor oral intake, fever, sweating) leading to low urine flow.
5. WARNINGS AND PRECAUTIONS; Information for Patients
Other nephrotoxic drugs used at the same time: aminoglycosides (e.g., gentamicin), amphotericin B, cisplatin, cyclosporine, tacrolimus, NSAIDs, vancomycin, and some diuretics.
5. WARNINGS AND PRECAUTIONS; 7. DRUG INTERACTIONS
In patients at higher risk, clinicians will often reduce the IV dose or extend the interval and ensure adequate hydration.
2. DOSAGE AND ADMINISTRATION; 5. PRECAUTIONS
To minimize risk, avoid rapid IV administration, maintain good urine output with fluids, and monitor kidney function (creatinine, BUN) and electrolytes during therapy.
2. DOSAGE AND ADMINISTRATION; 5. WARNINGS AND PRECAUTIONS; Information for Patients
If kidney function worsens or urine output drops, dosing should be adjusted per renal function, and nephrotoxic drugs should be reviewed.
2. DOSAGE AND ADMINISTRATION; 5. PRECAUTIONS
If you’re caring for someone on acyclovir and notice reduced urine output, swelling, fatigue, or other signs of kidney trouble, contact a clinician promptly.
Information for Patients; 5. WARNINGS
Unsupported Statements
Intravenous (IV) use has a higher risk than oral.
Not explicitly stated in the provided label sections.
High IV doses or frequent dosing (high total daily dose) increase risk.
Not explicitly stated in the provided label sections.
Conditions that reduce renal perfusion (e.g., heart failure, sepsis).
Not explicitly stated as a risk factor in the provided label sections.
Drugs that compete for renal tubular secretion (e.g., probenecid) can raise acyclovir levels and risk.
Not described in the provided Drug Interactions section.
Urinary obstruction or other factors that reduce urine flow.
Not explicitly described as risk factors in the provided label sections.
Severe dehydration risk states (burns, inadequate fluid intake) and sepsis.
Not explicitly described as a risk state in the provided label sections.
Contradictions
Important Omissions
No explicit mention of boxed warnings in the provided label sections; limited explicit discussion of IV vs oral risk comparisons; no detailed storage/handling information beyond general content.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Nephrotoxicity risk is present but mitigable with hydration, renal dosing adjustments, and avoidance of nephrotoxins; multiple accurate statements align with WARNINGS and DOSAGE sections.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Partial support for several claims (e.g., IV vs oral risk, perfusion-related factors) and some omissions.
Suggested Improvement
Clarify which nephrotoxicity risk statements are explicitly supported by the label; ensure claims about intravenous infusion rates and perfusion-related risk align with the exact language in the label; clearly categorize partial supports and provide explicit citations for each claim.